NCT02574377View on ClinicalTrials.gov

myDC/pDC in Stage III Melanoma Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Melanoma
Interventions
DRUG

A: myDC vaccination

DRUG

B: pDC vaccination

DRUG

C: combined myDC/pDC vaccination

Trial Locations (1)

6500 HB

Radboud University Nijmegen Medical Centre, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

NCT02574377 - myDC/pDC in Stage III Melanoma Patients | Biotech Hunter | Biotech Hunter